-+ 0.00%
-+ 0.00%
-+ 0.00%

BriaCell FY26 Q3 net loss widens to $7.24 million

PUBT·06/09/2026 20:07:28
Listen to the news
BriaCell FY26 Q3 net loss widens to $7.24 million
  • Briacell posted a Q3 net loss of USD 7.24 million, widening from USD 6.22 million a year earlier.
  • Operating loss widened to USD 7.62 million as operating expenses climbed to USD 7.62 million, led by R&D rising to USD 5.97 million.
  • Nine-month net loss widened to USD 22.81 million, while R&D and clinical trial spending increased to USD 18.7 million from USD 14.16 million.
  • Working capital rose to USD 21.8 million at April 30, 2026, with cash and cash equivalents down USD 3.61 million since July 31, 2025.
  • Phase 3 Bria-IMT enrollment surpassed 230 patients; FDA cleared Bria-BRES+ to start a Phase 1/2a study in metastatic breast cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Briacell Therapeutics Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-027928), on June 09, 2026, and is solely responsible for the information contained therein.